Long‐Term Safety and Clinical Effects of Nilotinib in Parkinson's Disease

BACKGROUND: Nilotinib is US Food and Drug Administration–approved for leukemia, and this open‐label study investigated the safety, tolerability, and potential clinical effects of nilotinib in medically optimized patients with Parkinson's disease. OBJECTIVES: Safety and tolerability were the pri...

Descripción completa

Detalles Bibliográficos
Autores principales: Pagan, Fernando L., Wilmarth, Barbara, Torres‐Yaghi, Yasar, Hebron, Michaeline L., Mulki, Sanjana, Ferrante, Dalila, Matar, Sara, Ahn, Jaeil, Moussa, Charbel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Regular Issue Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048914/
https://www.ncbi.nlm.nih.gov/pubmed/33215762
http://dx.doi.org/10.1002/mds.28389

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048914/
https://www.ncbi.nlm.nih.gov/pubmed/33215762
http://dx.doi.org/10.1002/mds.28389

Ejemplares similares